April 18 (Reuters) - The U.S. Food and Drug Administration approved the extended use of Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
(Reporting by Christy Santhosh and Gnaneshwar Rajan in Bengaluru; Editing by Alison Williams)
((Gnaneshwar.Rajan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。